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Part 1:
Synthesis of Half-Loaded Nitroimidazole Indocyanine Green Dyes
Attached to Carbon Nanotubes

Courtney Stanford, M.S.
University of Connecticut 2012
Part 1:
Indocyanine green dye is the only FDA approved NIR fluorescent dye that can be
used in humans. 2-Nitroimidazoles are very effective radiosensitizers, have low
cytotoxicity, and target hypoxic tissue. By coupling the two together, hypoxic tumors
can be targeted and imaged. Previous work has been done to couple 2-nitroimidazole to
both sides of the indocyanine green dye. This work focuses on expanding that concept
to couple 2-nitroimidazole to only one side of the dye, thus allowing for the other end to
be available to couple to another compound, generating a half loaded 2-nitroimidazole
indocyanine green dye. In theory, this half-loaded dye can be coupled to various
compounds resulting in unique properties for the dye. Our focus was on coupling the
half-loaded 2-nitroimidazole indocyanine green dye to single-walled carbon nanotubes
which also have fluorescent properties. It is hoped that more dye will be carried to the
hypoxic tumor leading to an increase in the observed fluorescence, and dye retention in
the tumor for an extended period of time.
Multiple half-loaded nitroimidazole ICG dyes were synthesized. The half-loaded
2-nitro ethanolamine carboxylic acid ICG was chosen to be coupled to the amine
functionalized nanotubes. The biological results for this product are pending, as of the
writing of this thesis.
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1. Introduction

The goal of this project is to attach an unsymmetrical 2-nitroimidazole
indocyanine green dye (ICG) conjugate to a single-walled carbon nanotube (SWNT). In
principle, this dye-conjugate will selectively target hypoxic tumors and be retained in the
tumor for a longer period of time relative to dye-conjugates not bound to SWNT. Tumor
imaging will be accomplished in living mice using a near-infrared fluorescence imaging
device developed by Professor Quing Zhu from the University of Connecticut
Department of Electrical and Computer Engineering. Since the SWNT also have
fluorescent properties, there may be an increase in the observed fluorescence of the
cancerous tumor, thus creating a better dye for use in fluorescent imaging techniques.

1.1 Cancer and Hypoxia
Cancer is a term used to describe numerous diseases characterized by an
unregulated growth of cells. As cells grow and divide, errors can occur in the sequencing
of DNA, damaging the DNA. DNA can also be damaged from UV radiation, nuclear
radiation and various chemicals. Normally, there are mechanisms in place to correct
these errors, so the mutated cells do not multiply. However, at times, these mechanisms
fail and the mutations are passed on to the next cell. When this happens, the cell can
begin to spontaneously replicate, inhibiting apoptosis. When these mutated cells begin to
form a mass, it is categorized as a tumor.1
As the tumor grows, it forms its own network of blood vessels via angiogenesis.
Since many tumors grow quickly, the result is a disorganized and leaky vascular network.

1

Eventually, the tumor will outgrow its vascular network, and less oxygen is available to
the cells. When cells have an inadequate supply of oxygen, a tumor-specific hypoxic
microenvironment can be generated and biological functions are compromised. Hypoxia
is characterized by low oxygen partial pressure, low pH, and low glucose concentration.2
Tumor cells are able to adapt to this new hypoxic environment, which can lead to
resistance in cancer therapies. When healthy cells are deprived of oxygen, they
eventually die. As a tumor expands and outgrows its vascular network, it is able to slow
its growth rate which decreases perfusion. This can inhibit the effectiveness of most
chemotherapy drugs, which are essentially antiproliferation agents, because conventional
drugs are generally toxic to cells at a level that is proportional to proliferation.3
Another method in the treatment of cancer is radiation therapy. Radiation therapy
uses photons to directly or indirectly ionize atoms in DNA.4 When O2 is irradiated, the
ground state triplet oxygen is excited into singlet state oxygen, which generates hydroxyl
radicals. These radicals kill cells in their immediate area by damaging the DNA resulting
in cell death. Since singlet oxygen has a short lifetime in water, it cannot diffuse very far
and, therefore, specific areas in the body can be easily targeted.5 Molecular oxygen is a
potent chemical radiosensitizer, a chemical that is able to increase the effectiveness of the
radiation therapy, because it is an extremely electron-affinic molecule. However,
radiation has very little effect on hypoxic tumors, due to the low levels of oxygen present
in the cells. The free radicals that are formed by ionizing radiation recombine without
causing damage to the DNA. Hypoxic cells that lack oxygen are about three times more
resistant to radiation than cells that are well oxygenated at the time of irradiation.6
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Understanding the microenvironment of a tumor is important because it dictates
how effective radiation therapy will be, and how a chemotherapeutic drug can be
delivered. Traditional chemotherapies do not account for this.7 In general, being able to
identify tumor hypoxia is a key factor in determining what type of cancer therapy would
be most successful for patients.

1.2 Imaging Techniques
There are several current techniques, both invasive and non-invasive, used to
identify tumor hypoxia. One technique uses oxygen sensitive electrodes.3 Using these
electrodes, the partial pressure of O2 in-vivo can be measured. However, this technique
has limits. The signal generated is very small within the range of cell-threatening
hypoxia since the electrode consumes oxygen by electrochemical reduction. These
electrodes also require the use of computed tomography (CT), can only access tumors
close to the surface of the body (such as the cervix3, head, and neck8), are invasive, and
can damage the tissue.3
Fiber optic probes have been used in the measurement of pO2. These probes work
by using an optical fiber to carry fluorescent pulses. These pulses are inversely
proportional to the partial pressure of the oxygen. Equilibrium with the pO2 in the tissue
allows for a continuous reading of the pO2. These probes are smaller than the oxygen
sensitive electrode and are less damaging to tissues, but only a small area can be sampled
at a time.9
Non-invasive techniques exist such as positron emission tomography (PET) and
magnetic resonance imaging (MRI). PET is a technique that produces a three-
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dimensional image of the body. A three-dimensional image is possible because of the
radiation released by a positron-emitting radioactive tracer that is introduced into the
body. The most widely used PET imaging agent for hypoxia is 18F-labeled
fluoromisonidazole (1), an 18F-labeled nitroimidazole. (See Figure 1) The delivery of this
compound is not limited by perfusion, and its retention within tissues is dependent on
nitroreductase activity the reduction status of a NO2 group on the imidazole ring.7
Fluoromisonidazole has been shown to be retained in tumors and to cross the blood brain
barrier. Drawbacks include low imaging contrast, a high retention in the liver, and a
twenty-four hour resting period between repeated doses.10

Figure 1: Structure of Fluoromisonidazole (1)
An MRI uses a magnet to align nuclei in the body, and a radio frequency field is
applied to systematically alter this alignment. Under these conditions, the nuclei will
produce a rotating magnetic field, which is then detected and constructed into an image
of the body. Using contrast agents and tracers, an estimation of tumor permeability can
be determined.7 There are multiple types of MRIs; each type provides different
characteristics of a tumor.

19

F-MRI uses fluorine-containing contrast agents, which are

sensitive to oxygen concentration. The MRI can then highlight the differences in oxygen
concentration.7 Dynamic contrast-enhanced MRI (DCE-MRI) is a technique using
various types of contrast agent that give information about the properties of tumors such
as distribution volume, permeability, and perfusion.7 Blood oxygen level-dependent MRI
4

(BOLD-MRI) relies on the imbalance between paramagnetic deoxyhemoglobin and
diamagnetic oxyhemoglobin to image tumors. However, this technique is not
quantitative.7 Both PET and MRIs have drawbacks as well. They are both expensive
techniques for routine clinical use in longitudinal imaging assessments over the course of
neoadjuvant chemotherapy. Thus, a new low-cost, non-invasive technique for the
analysis of tumor hypoxia is an attractive goal.
Near Infrared (NIR) Fluorescence Diffuse Optical Tomography (FDOT) is a
technique that has the potential to be of great use in the detection of hypoxia. In the NIR
range, human tissue has relatively low absorption and relatively high scattering, thus
allowing NIR light to pass through most tissue.11 FDOT is a technique that has the
ability to produce images of absorption and scattering. With the addition of a fluorescent
dye that has the ability to target tumors, this technique can provide greater sensitivity and
specificity about the tissue being analyzed due to the dye’s fluorescent signals.
Fluorescent signals can be detected in tumors up to 2.0 to 3.0 cm from the skin surface,
which are then reconstructed into an image, giving insight into the tumor
microenviroment.

Figure 2: Image of 2-nitropiperazine ICG inside mouse tumor after 10 minutes
using NIR-FDOT
5

From this information, the concentration of oxygen in the hemoglobin and the pH
can be determined.11, 12 NIR-FDOT is most successful with a fluorescent dye that has an
emission in the 700 – 850 nm range, has a high extinction coefficient, and a high
fluorescent yield. Other characteristics of NIR-FDOT dyes include water solubility, nontoxicity, and the ability to easily bind to biological molecules. NIR-FDOT has
advantages over other techniques because it is low cost, is portable, has repeatability in
longitudinal imaging, and has little background fluorescence.

1.3 Indocyanine Green and Nitroimidazoles
Indocyanine green dye (ICG, 2, shown in Figure 3) meets the requirements of an
NIR-FDOT dye. This NIR fluorescent dye has an emission peak ~807 nm, and is the
only FDA approved agent that can be used in humans, due to its low toxicity and high
absorbance in the NIR spectrum. Studies in animal models13,14 and in humans15,16 have
demonstrated its ability to enhance tumor contrast. However, there are disadvantages to
using ICG: 1) it is very non-specific due to binding to plasma proteins, which causes it to
quickly wash out of the body and tumor site; 2) it is optically unstable in the body; 3) it
has a low quantum yield.17, 18 These issues can be mediated with a dye that can target
tumors specifically, and can be retained in the body for longer durations of time.
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Figure 3: Structure of Indocyanine Green (2)
The family of compounds based on nitroimidazole has a high electron affinity and
shows selectivity towards hypoxic cells. This increased sensitivity is due to an enzymemediated four-electron reduction, which causes the nitroimidazole molecules to
accumulate in hypoxic areas of a tumor. P-450 reductase is responsible for the radical
reduction of nitroimidazole. The actual mechanism for this is still unknown, but a
plausible mechanism has been proposed and is shown in Scheme 1.19,20 The reduced
forms of nitroimidazole eventually links with macromolecules, helping to be retained in
the hypoxic regions. This sensitivity to hypoxic areas differs from normal tissue because
oxygen has been found to efficiently hinder the reduction of nitroimidazole by reversing
it. 21,22 Hypoxic areas contain low O2 levels, limiting the effects of radiation therapy.
This is because lower amounts of hydroxyl radicals are produced. Nitroimidazoles are
bio-active radiosensitizers that make tumor cells more sensitive to radiation therapy.23
Radiosensitizers mimic the hydroxyl radicals, increasing the effectiveness of the radiation
therapy.

7

Scheme 1: Plausible Mechanism for the Reduction of Nitroimidazoles24
To date several members of the nitroimidazole family have been studied, the first
being metronidazole, a 5-nitroimidazole, discovered in the late 1950’s. Metronidazole
(3) is used primarily as an antibiotic, amebicide, and antiprotozoal.23 Over time,
scientists have improved the effectiveness and application for nitroimidazoles. Other
prominent 5-nitroimidazole compounds are tinidazole (4) and ornidazole (5). Both are
antiprotozoal drugs in use today.23 (Figure 4)

Figure 4: Structures of 5-nitroimidazole derivatives: metronidazole (3),
tinidazole (4), and ornidazole (5)
While metronidazole has been shown to be a hypoxic sensitizer, high
concentrations are needed for it to be effective.25 Thus, other nitroimiazoles such as
misonidazole (6),25 pimonidazol (7),26 and etanidazole (8)27 (Figure 5) are currently being
analyzed. These studies have shown that 2-nitroimidazoles are very effective sensitizers,
and have low cytotoxicity. Of particular interest to us is etanidazole (8); a good
radiosensitizer and less toxic than misonidazole (6).27 It can also bind to ICG dye via an
ester bond at its primary alcohol.

8

Figure 5: Structures of 2-nitroimidazoles derivatives misonidazole (6),
pimonidazole (7), and etanidazole (8)
In order to use the nitroimidazole group to target a hypoxic tumor, a way to
conjugate the nitroimidazole to the ICG dye was required. This problem was solved by
using a known bis-carboxylic acid derivative of ICG (9).28 (Figure 6)
O
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9
bis-carboxylic acid ICG

Figure 6: Structure of bis-carboxylic acid ICG (9)
Research has shown that both the bis-carboxylic acid ICG (9) and the 2nitroimidazole ICG have an excitation peak at 755 nm and fluorescence emission peak at
778 nm. The latter has a quantum yield of 0.066, while ICG has a quantum yield of
0.012.18 The increase in the fluorescence quantum yield is most likely due to the
formation of fluorescence-quenched aggregates that are suppressed because dye-dye
interaction and aggregation is reduced by hydrophilic, non-charged but sterically
demanding substituents.29,30 Several routes for the synthesis of the bis-carboxylic acid
9

ICG (9) have been developed by Lindsey,28 Ozinskas,31 Licha,29 and Smith.17 The Smith
group used these precedents to develop a method for attaching etanidazole (8) to the biscarboxylic ICG (9), resulting in a 2-nitroimidazole ethanolamine ICG (10).17 (Figure 7)

Figure 7: Structure of 2-nitroethanolamine ICG (10)
Based on this work, other 2-nitroimidazole derivatives could also be attached to
the bis-carboxylic acid ICG (9), specifically a 2-nitroimidazole with a piperazine linker
instead of an ethanolamine linker. It is believed that this derivative would be more robust
in vivo since amide bonds are less susceptible to hydrolysis. Also of note is the fact that
2-nitroimidazole ethanolamine ICG (10) is a symmetrical dye. If the dye could be altered
slightly to become unsymmetrical, then the dye could have both a 2-nitroimidazole and
another compound attached to it simultaneously to generate a half-loaded dye (Figure 8).
This new dye would include the fluorescence ability of the ICG, the hypoxic tumor
targeting ability of the nitroimidazole, and the ability of the other compound that could be
attached to the half-loaded ICG dye.
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Figure 8: Structures of Half-Loaded ICG Derivatives (11) and (12)

1.4 Carbon Nanotubes
Several different compounds can be attached to these unsymmetrical ICG dyes
(11, 12), including single-wall carbon nanotubes (SWNTs). SWNTs have unique
properties due to their one-dimensional structure, including high tensile strength and
resilience, plus a high thermal and current carrying capacity.32 The ability to
functionalize these nanotubes can lead to the development of more novel or enhanced
properties.33 Currently SWNTs are being chemically altered via oxidation of their
fullerene-like caps followed by different reactions with the carboxylic groups.34,35
Another method, using free radical addition of alkyl groups ending in carboxylic acids,
has allowed for the addition of functional groups to the side wall of the SWNT.36 Once
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an acid functionalized nanotube exists, the addition of other functional groups such as
amines is easily achieved.36 With a SWNT ending in an amine, it is possible to attach
multiple unsymmetrical 2-nitroimidazole half-loaded dyes (11, 12) to the nanotube via an
amide bond. This is important because it has been shown that carbonaceous materials
can promote the intensification and/or prolongation of the excited states of dyes, due to
charge-transfer interactions.37 Dyes that have been studied in this fashion include the
phenazine dyes phenosafranine (13) and Nile Blue (14).
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H2N
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NH2

H2N

O

N
SO42-

Cl
N
2

13
phenosafranine

14
Nile Blue

Figure 9: Structures of Phenosafranine (13) and Nile Blue (14): Dyes Previously
Attached to SWNTs
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2. Results and Discussion

2.1 Formation of Bis-Carboxylic Acid ICG, (9)
To the best of our knowledge, there is currently no known FDOT selective
hypoxic targeting probe that fluoresces in the near infrared region (700-850 nm).
Currently, the only NIR fluorescent dye approved by the FDA is indocyanine green, due
to its low toxicity. Studies have shown that ICG enhances tumor contrast, but it is
nonspecific and quickly eliminated from the body.17, 18 The main goal of this work is the
synthesis of a fluorescent ICG dye that can be used to detect and image hypoxic
cancerous tumors.
The complete synthesis of the bis-carboxylic acid ICG can be seen in Scheme 2.17
Beginning with a Fischer-indole reaction, 4-hydrazinobenzoic acid (15) and 3-methyl 2butanone were reacted to yield the carboxylic acid indole (16) in 68% yield. The
duration of this reaction varied based on the age of the acetic acid-reaction times ranged
from 12 hours to 48 hours. Next, the carboxylic acid indole (16) was heated at reflux
with 1,4 butanesultone in 1,2 dichlorobenzene overnight to yield the carboxylic acid
indolium salt (17) in 88% yield. The last step is a reaction in which N-[5-(Phenylamino)2,4-pentadienylidene]aniline monohydrochloride is used as a linker to connect two of the
carboxylic acid indolium salt (17) by refluxing in acetic acid and acetic anhydride with
sodium acetate, forming the bis-carboxylic acid ICG (9) in 80% yield. It is easy to
identify when this reaction has gone to completion because the reaction mixture changes
from a brunt red to blue-green in color. The overall yield of 9 from 15 is 48%.
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Scheme 2: Formation of bis-carboxylic acid ICG (9)

2.2 Formation of Methyl Ester – Acid ICG, (18)
The bis-carboxylic acid ICG (9) is a symmetrical dye, so it is difficult to perform
a reaction that would allow only one of the carboxylic acid groups to react. To solve this
dilemma an unsymmetrical dye must be generated to allow for the reaction of only one
end of the dye at a time, resulting in a half-loaded dye. This unsymmetrical dye would
require one of the carboxylic acid groups to be blocked off, so it would be unreactive
towards any reaction that would add the nitroimidazole to the carboxylic acid end of the
ICG. It is hoped that by protecting one end of the dye, a higher yield of mono-substituted
dye can be generated. To block off one end, a methyl ester was chosen due to the ease of
removal, thus forming a methyl ester–acid ICG dye (18). The formation of a methyl
ester-acid dye would be useful because it would allow for two different compounds to be
added to each end of the ICG dye. This ability would increase the functionality of the
dye and allow it to have multiple unique properties.

14

Figure 10: Structure of Methyl Ester-Acid ICG Dye
The formation of the methyl ester-acid ICG (18) is similar to the formation of the
bis-carboxylic acid ICG (9). In order to make the methyl ester-acid ICG (18),
methodology was required that converted one of the carboxylic acid groups to a methyl
ester group. One method would form a methyl ester indolium salt (19) and react it with a
carboxylic acid indolium salt (17) to generate the final dye. There are three steps
preceding the formation of the bis-carboxylic acid dye, and a methylated intermediate
was prepared for each in an attempt to determine which was the best.
First, the 4-hydrazinobenzoic acid (15) was methylated using oxalyl chloride and
methanol, but the product was methyl 4-(1,2,2-trimethylhydrazinyl)benzoate (20). Next,
the carboxylic acid indoline (16) was methylated using oxalyl chloride and methanol,
giving methyl ester indoline (21). This methyl ester indoline was reacted with 1,4butanesultone to form the methyl ester indolium salt (19). However, it was very difficult
to isolate the product because the solvent was 1,2 dichlorobenzene and the product would
not crystallize. In addition, it was difficult to remove all of the solvent from the product.
Lastly, the carboxylic acid indolium salt (17) was methylated with oxalyl chloride in
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methanol. This resulted in the methyl ester indolium salt (19), which was easily isolated
after stirring the crude product in ether. (Scheme 3)

Scheme 3: Formation of Methylated Products
The difference between the carboxylic acid indolium salt (17) and the methyl
ester indolium salt (19) can be easily seen in the 1H NMR. At 3.98 ppm in MeOD, the
methyl ester can be distinctly seen. The peak at 3.86 ppm is a side product from the
reaction that could not be completely removed, but it does not carry on to the next step of
the synthesis. This impurity could not be identified because it only showed a singlet in
the 1H NMR, one peak in the 13C NMR, and a mass spec could not be obtained.
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Figure 11: 1H NMR of Carboxylic Acid Indolium Salt (17) - Solvent: CD3OD
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Figure 12: 1H NMR of Methyl Ester Indolium Salt (19) – Solvent CD3OD
With the methyl ester indolium salt (19), the methyl ester-acid dye (18) could be
formed based on stoichiometry. The mechanism shows that the reaction between the two
indolium salts is a stepwise process (Figure 13). Using one molar equivalent of methyl
ester indolium salt (19), one molar equivalent of carboxylic acid indolium salt (17), and
one molar equivalent of N-[5-(Phenylamino)-2,4-pentadienylidene] aniline
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monohydrochloride, the methyl-ester acid dye (18) was generated in 83% yield, with an
overall yield of 48%.

Figure 13: Proposed Mechanism for Formation of Mechanism for the Methyl EsterAcid Dye (18)
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Scheme 4: Formation of Ester-Acid ICG (18)
The synthesis of the methyl ester-acid ICG dye (18) requires specific timing. The
proposed mechanism (Figure 13) shows that reaction with the indolium salts is a stepwise
process. The carboxylic acid indolium salt (17) and the bis-anilide linking unit is added
at the beginning of the reaction and refluxed for 30 minutes. At that time, the methyl
ester indolium salt (19) is added, and the system is heated at reflux for an additional 45
minutes. If the methyl ester indolium salt (19) is added before the 30 minutes,
incomplete reaction of the carboxylic acid indolium salt (17) leads to lower yields, and
addition much after the 30 minutes the carboxylic acid indolium salt (17) leads to
reaction on both sides. The consequence is that the product is a mixture of acid-acid dye,
acid-ester dye, and ester-ester dye. Even with close monitoring of the stoichiometry and
the reaction time, a very small amount of bis-carboxylic acid ICG (9) is formed.
As with the bis-carboxylic acid ICG (9), completion of the reaction can be
monitored by color change. Upon addition of the first indolium salt, the reaction mixture
remains red. Once the second molar equivalent of indolium salt has been added to the
mixture, it begins to turn a blue green color, which is an indication that both sides of the
bis-anilide linker have attached to an indolium salt. Theoretically, the methyl ester
indolium salt (19) could be added first, then the carboxylic acid indolium salt (17),
resulting in a small amount of ester-ester dye. The small amount of byproduct is not
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separated at this point, but will be separated out after the coupling with the nitroimidazole
moieties. This protocol was followed to minimize hydrolysis of the methyl ester-acid
ICG dye (18) to the bis-carboxylic acid ICG (9), as tracked by TLC analysis.
Analysis of the NMR spectra shows a difference between the symmetrical and the
unsymmetrical dyes. Figure 14 is the 1H NMR for the bis-carboxylic acid ICG (9) and
Figure 15 is the 1H NMR for the methyl ester-acid ICG (18). Both NMRs are similar, yet
a few differences can distinguish the two. The first being the CH3 of the methyl ester at
3.86 ppm in the methyl ester-acid ICG (18). There is an increase in splitting showing
how the molecule is no longer symmetrical. The hydrogens of the amino methylenes of
the sulfonate chains, in the symmetrical dye produce a broad singlet at 4.11 ppm. These
become two broad singlets at 4.11 and 4.15 ppm in the unsymmetrical dye. Increase in
splitting of the aromatic protons can also be seen as well, this is thought to be due to the
positioning of the carbonyl groups off the aromatic ring.
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Figure 15: 1H NMR of Methyl Ester-Acid ICG (18) – Solvent DMSO
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2.3 Formation of Nitroimidazole Derivatives
Nitroimidazoles are bio-active radiosensitizers that have a high electron affinity
and are selectively sensitive towards hypoxic cells. This sensitivity makes them useful
for targeting hypoxic tumors. Attaching a nitroimidazole unit to the ICG dye would
allow targeting of a hypoxic tumor. Carrying the fluorescent dye with it, this would
allow imaging of the tumor using NIR-FDOT imaging techniques.
2-Nitroimidazole has been shown to selectively target hypoxic regions in the
body, so attachment to the fluorescent dye seemed to be a reasonable goal. This required
the development of synthetic methodology. However, due to the price of 2nitroimidazole ($293.00 per gram) the methodology was tested on 4-nitroimidazole. This
compound is cheaper ($1.62 per gram), but exhibits little or no hypoxic targeting
capability. It is noted that 4-nitroimidazole is the normal product formed by electrophilic
aromatic nitration of imidazole.
The synthetic nitroimidazole compounds are to be linked to the ICG dyes via the
carboxylic acid, but there must be a linker between the nitroimidazole and the ICG dye.
The first linker was an ethanolamine unit, as shown in Scheme 5. This linker could be
attached to a nitroimidazole acetate derivative. Therefore, a nitroimidazole (22a, 22b)
reacts with methyl α-bromoacetate to give 4-nitroimidazole methyl ester (23a) in 75%
yield or 2-nitroimidazole methyl ester (23b) in 36% yield. This nitroimidazole methyl
ester (23a, 23b) was then stirred with ethanolamine in methanol at room temperature to
give the 4-nitroimidazole ethanolamine (24a) in 81% yield, with an overall yield of 61%
and 2-nitroimidazole ethanolamine (24b) in 95% yield, with an overall yield of 34%.
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Scheme 5: Synthesis of Nitroimidazole Ethanolamine Derivatives
Piperazine was analyzed as another linker in the hope it would be more robust
than the ethanolamine linker due to the formation of two amide bonds. As before the
nitroimidazole (22a, 22b) was converted into the methyl ester (23a, 23b), and then
reacted with mono-BOC protected piperazine (25), prepared by the treatment of
piperazine (26) with di-tert-butyl dicarbonate. (Scheme 6) Both mono- and disubsitituted piperazine were formed, but the compounds did not require separation
because the di-substituted product could not react in the next step of the synthesis.
However, after several failed attempts at coupling the nitroimidazole methyl ester (23a,
23b) with the mono-BOC protected piperazine (25) using DIPEA, it was determined that
the reactivity of the nitroimidazole compound had to be increased.
H
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H
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Scheme 6: Synthesis of Mono-BOC Protected Piperazine
To increase reactivity, the methyl ester (23a) was hydrolyzed to the carboxylic
acid (27) in 97% yield by refluxing in water overnight (Scheme 7). The acid was easily
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converted into the acid chloride (28) via reaction with oxalyl chloride. (Scheme 8) The
acid chloride, remained in situ and was reacted with the secondary amine of the monoprotected BOC piperazine (25) to produce the 4-nitroimidazole BOC-protected piperzine
(29) in 23% yield. Once the piperazine unit was attached, the compound was deprotected
using TFA to give the 4-nitroimidazole piperazine TFA salt (30) in 94% yield, giving an
overall yield of 16%.

Scheme 7: Synthesis of Nitroimidazole Acid
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Scheme 8: Synthesis of 4-Nitroimidazole Piperazine Derivative (30)
The addition of piperazine to the 4-nitroimidazole was examined in an attempt to
increase the yield, using various protecting groups as well as unprotected piperazine.
We found that TMS and TES were not useful as protecting groups for piperazine. When
unprotected piperazine reacted with the acid chloride (28), the products were a mixture of
unreacted nitroimidazole, monosubstituted nitroimidazole piperazine, and disubstituted
nitroimidazole piperazine.
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Interestingly, attaching piperazine (26) to the nitroimidazole via an acid chloride
works for the 4-nitroimidazole (22a), but the procedure could not be carried over to the 2nitroimidazole (22b). After 24 hours of heating at reflux in water the 2-nitroimidazole
methyl ester (23b) could not be converted into the 2-nitroimidazole acid (27b). This is
thought to be because the electronics between the 4-nitroimidazole and the 2nitroimidazole are different.
The preparation of the biologically active 2-nitroimidazole target required another
procedure to attach the piperazine unit. The procedure shown in Scheme 8 was
developed by Mr. Innus Mohammed. Previous experience showed that it was difficult to
attach the secondary amine of the protected piperazine to the nitroimidazole with the
carbonyl group already attached to it because of inactivation of the carbonyl to react with
the secondary amine of the piperazine. This synthesis of 2-nitroimidazole piperazine
TFA salt (31) begins with the mono-BOC protected piperzine (25), which is converted
into bromoacetyl BOC-protected piperazine (32) using triethylamine and α-bromoacetyl
bromide (81%). Next with sodium hydride as the base, the 2-nitroimidazole (22b) is
deprotonated, then reacted with the bromoacetyl BOC-protected piperazine (32) in an
SN2 reaction to yield 2-nitroimidazole BOC-protected piperazine (33) with a 94% yield.
The BOC protecting group is removed the same way as before using TFA, to create the
2-nitroimidazole piperazine TFA salt (31) in 86%, with an overall yield of 65%.
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Scheme 9: Synthesis of 2-Nitroimidazole Piperazine Derivative (31)

2.4 Formation of ICG Conjugates
With the development of the methyl ester-acid dye (18) and the nitroimidazole
derivatives (24a, 24b, 30, 31), the two compounds must be coupled to give a dyeconjugate that combines the tumor targeting abilities of the nitroimidazoles with the
fluorescent abilities of the dye. Initially, this coupling was attempted with DCC, with
limited success, so a new procedure was developed. We found that DIPEA, PyBOP
(benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate), and HOBt
(hydroxybenzotriazole) could be used to couple the nitroimidazoles to the dye (Schemes
10 & 11). This reaction is useful in that it can be used to couple both the ethanolamine,
and piperazine linked nitroimidazoles. 24a was isolated as a dark purple solid in 20%
yield and 24b was isolated as a dark purple solid in 35% yield. 35 was never completely
isolated due to decomposition during workup.
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Scheme 10: Coupling of the Ethanolamine-Linked Nitroimidazole (24a, 24b) to the
Methyl Ester-Acid Dye (18)
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Scheme 11: Coupling of the Piperazine-Linked Nitroimidazole (30, 31) to the Methyl
Ester-Acid Dye (18)
Based on TLC analysis (Figure 16) multiple compounds are present after this
reaction. Since this reaction goes to equilibrium, the uncoupled dye must be separated
from the coupled dye, any bis-carboxylic acid ICG (9) that might be present should also
be easily removed. From the reverse phase TLC, the various spots could be identified
based on their Rf values. The topmost spot is the bis-carboxylic acid ICG (9) Rf = 0.76,
followed by the unreacted methyl ester-acid ICG (18) Rf = 0.67, then the bis-carboxylic
acid ICG that has the nitroimidzole coupled on both sides Rf = 0.36, and lastly the half
loaded dye (34b) Rf = 0.28.
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Figure 16: Reverse Phase TLC Analysis for Half-Loaded Dyes
Due to the polarity of these compounds, C-18 reverse phase silica gel was used to
separate the product from the starting material. This greatly limits the solvent systems
that can be used. Only water, methanol, and acetonitrile may be used on C-18 reverse
phase silica gel. After many failed attempts to separate the compounds on a manual
column, it was determined that Combi Flash, or an automated column must be used. 30%
acetonitrile in water gave the best separation on TLC however, 40% methanol in water,
was necessary for solubility reasons for the reverse phase column chromatography. With
the hope of avoiding this difficult separation, other coupling reagents such HBTU (O(Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium Hexafluorophosphate) and DMTMM
(4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride) will be tested to
see if they improve the coupling. Both are commonly used coupling reagents used for
coupling secondary amines in peptides.
NMR analysis can easily show the difference between the methyl ester-acid dye
(18) (Figure 17), and a methyl ester-acid dye coupled to a nitroimidazole such as the 4nitroimidazole ethanolamine methyl ester-acid ICG (34a) (Figure 18). Only one 4-
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nitroimidazole ethanolamine has been attached to the ester acid dye based on a) the two
peaks at 8.31 and 7.80 ppm which are the two hydrogens on the nitroimidazole and b) the
peaks at 4.88, 4.31, and 3.52 ppm which belong to the CH2 groups of the 4nitroimidazole ethanolamine. The peak at 3.69 ppm indicating the presence of the methyl
ester. It should be noted that Figure 18 has a very low concentration of the sample
present.
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Figure 17: 1H NMR of Methyl Ester-Acid ICG (18) – Solvent DMSO
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Figure 18: 1H NMR of 4-Nitroimidazole Ethanolamine Methyl Ester-Acid ICG (34a)
– Solvent DMSO
Several attempts of hydrolyzing the methyl ester were met with repeated failure.
Water hydrolysis, acid-catalyzed hydrolysis using 1 M HCl, and base catalyzed
hydrolysis using 2.5% NaOH all resulted in degrading the compound, based on TLC
analysis. When other conditions for hydrolysis were used including barium hydroxide
octahydrate (nonaqueous media) and aluminum chloride with N,N-dimethylaniline, no
reaction took place. It is believed that this hydrolysis failed because these compounds
are too sensitive to be hydrolyzed by an acid or base in aqueous media, and the other
reagent may not have been able to overcome the activation energy to react.
Due to multiple failed attempts at removing the methyl ester, coupling between
the bis-carboxylic acid ICG (9) and the various nitroimidazole moieties was carried out
with one molar equivalence of dye, and one molar equivalence of a nitroimidazole
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derivative. It was initially hoped that by using the methyl ester to block one end of the
dye a higher yield could be obtained for the half load dyes, since only one end of the dye
was available for coupling at a time. Using the same conditions as before, as shown in
schemes 12 and 13, each of the nitroimidazoles were coupled to the bis-carboxylic acid
ICG (9), and then separated on the Combi Flash, resulting in the synthesis of the halfloaded ICG dyes 36a, 36b, 37a, and 37b. The yields for the following compounds are as
follows 33% for 36a, 72% for 36b, 16% for 37a, 37b was never made due to time
constraints. 36b was not passed through the Combi Flash, resulting in the difference in
yield.
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Scheme 12: Coupling of the Ethanolamine Linked Nitroimidazole (24a, 24b) to the
Bis-Carboxylic Acid Dye (9)
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Scheme 13: Coupling of the Piperazine Linked Nitroimidazole (30, 31) to the BisCarboxylic Acid Dye (9)
Based on NMR analysis key differences can be seen the bis-carboxylic acid ICG
(8) (Figure 14) and the nitroimidazole moieties. Figure 19 shows the 1H NMR of 4nitroimidazole ethanolamine acid ICG (36a) key peaks to look at include a) the two peaks
at 8.31 and 7.80 ppm which are the two hydrogens on the nitroimidazole and b) the peaks
at 4.88, 4.31, and 3.52 ppm which belong to the CH2 groups of the 4-nitroimidazole
ethanolamine and c) 12.93 ppm which is the hydrogen for the acid. Differences can also
be seen between the 1H NMR of 4-nitroimidazole piperazine acid ICG (37a) (Figure 20).
Here the piperazine peaks can be seen at 3.11 and 3.60 ppm as well as the acid peak at
12.90 ppm.
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Figure 19: 1H NMR of 4-Nitroimidazole Ethanolamine Acid ICG (36a) – Solvent
DMSO

Figure 20: 1H NMR of 4-Nitroimidazole Piperazine Acid ICG (37a) – Solvent DMSO
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2.5 Formation of ICG – Nanotubes
Single Walled Nanotubes (SWNT) have found a wide range of uses due to their
unique chemical and physical properties. These compounds are incredibly strong, and
can greatly vary in length. One of the most remarkable features of certain nanotubes is
their ability to rapidly cross through cell membranes.38 This is of particular interest in the
medical and biological fields as compounds that express poor diffusion into cells could
be linked to SWNT to increase their delivery to cells. Nanotubes have also been shown
promote the intensification and/or prolongation of the excited states of dyes, due to
charge-transfer interactions.37
The SWNT used in this study were prepared by Mr. Saied Zanganeh from the
University of Connecticut Department of Electrical and Computer Engineering.
Commercially available SWNTs (38), were functionalized with a carboxylic acid
derivative by sonicating them in sulfuric acid and nitric acid, then adding hydrochloric
acid. The carboxylic acid functionalized nanotubes (39) was then converted into an acid
chloride (40) via thionyl chloride which was reacted with triethylenetetramine to generate
the amine functionalized single walled nanotube (41), as shown in Scheme 14.
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Scheme 14: Synthesis of Amine Funtionalized Nanotubes36
In order to attach the bis-carboxylic acid ICG (9) to the SWNT, it was
functionalized to give acid chloride (42) using oxalyl chloride, and then reacted with the
amine functionalized SWNT (41), binding the dye to the nanotube (43). Any excess dye
that did not bind to the nanotubes was washed off by immersion in water, followed by
passage through a fritted crucible. Since the dye is soluble in water and the nanotubes are
insoluble, the unbound dye can be easily separated. It is unknown exactly where the dye
binds to the amine, or exactly how much is bound because currently there is no way to
accurately quantify how many of the dye molecules have become attached to the
nanotubes, other than by weight difference.

36

Scheme 15: Synthesis of ICG Bound Nanotubes (43)36
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Since the nanotubes are insoluble in any NMR solvent, other methods had to be
used to analyze the compound. Analysis was attempted with two instruments, an IR
spectrometer and a Raman spectrometer. IR analysis was attempted on both Nexus 670
with DTGS detector and ATR attachment and a Bruker IFS 66v/S with MCT detector
using KBr pellets. Data was gathered on the bis-carboxylic acid ICG (9) and the biscarboxylic acid bound to the nanotubes (43). However, no data could be collected on the
non-coupled nanotubes (41). This is thought to be because the nanotubes are black and
the laser could not penetrate the sample. Therefore, there was no baseline to compare the
bis-carboxylic bound to the nanotubes (43) to. Luckily, the amine functionalized
nanotubes (41) could be analyzed with a Raman spectrometer, showing two significant
peaks in the Raman spectrum at 1587.48 cm-1 and 2666.44 cm-1. The bis-carboxylic
bound to the nanotubes (43) shows a peak at 1594.43 cm-1 which is shifted from 1587.48
cm-1 of the amine functionalized nanotubes. (Figure 21) Therefore it can be concluded
the amide peak connecting the ICG to the nanotube did form. Figure 22 shows the
Raman spectrum of bis-carboxylic acid ICG (9), similarities can be easily seen between
the bound and unbound ICG, specifically at 1140.39 cm-1 and 1373.58 cm-1.
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Figure 21: Raman Data Showing Amide Peak for ICG-Nanotube Connection
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2.6 Bioassay of ICG-Nanotubes
Initial biological studies in mice showed that the ICG bound nanotubes
congregated on the periphery of the hypoxic tumor, instead of penetrating the tumor.
Looking at the tumors under a microscope, after they have been removed from the
mouse, show the difference between the bis-carboxylic acid ICG (9) and the biscarboxylic acid ICG bound to the CNT (43). (Figure 23) This lack of penetration is
thought to be due to the size of the nanotubes, they might be too large to penetrate the
tumor. To see if this is truly the case, smaller nanotubes were used to attach ICG dye to
it. These smaller nanotubes are a few nanometers long, as opposed to the original
nanotubes which were micrometers long.

Figure 23: (a)Tumor with Bis-carboxylic acid ICG (b)Tumor with Bis-carboxylic
acid ICG Bound to Long Nanotubes – Unable to Penetrate the Tumor.
With the carboxylic acid half-loaded dyes (36a, 36b, 37a), the coupling of these
dyes to the amine functionalized nanotubes (41) could be achieved in the same manner
(Scheme 16). Coupling was done with 36, it was functionalized to give acid chloride
(44) using oxalyl chloride, and then reacted with the amine functionalized mini SWNT
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(41). Any excess dye that did not bind to the nanotubes was washed off by immersion in
water, followed by passage through a fritted crucible. This resulted in the each of the half
loaded dyes being bound to the mini nanotubes giving compounds 45. Using the Raman
spectrometer, a peak at 1599.50 cm-1 can be seen, indicating that the dye has bound to the
nanotubes.
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Figure 24: Raman Data Showing Half Loaded 2 Nitro Ethanolamine Acid Bound to
CNT

41

Scheme 16: Synthesis of Half Loaded Ethanolamine ICG Dyes Coupled to Carbon Nanotubes
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3. Conclusion
In conclusion the synthesis of the half-loaded nitroimidazole indocyanine green
dyes (36a, 36b, 37a) were achieved in 8-10% over 6-8 steps. By coupling the
nitroimidazole units to the bis-carboxylic acid ICG in 1:1 molar equivalencies, the half
loaded dye conjugates with a nitroimidazole on one end and a carboxylic acid on the
other were obtained. Initially, the nitroimidazole units were attached to the methyl esteracid ICG, which had one end blocked off, in order to enhance mono-substitution.
However, due to the inability to remove the methyl ester from the compound without
degradation, this route was not investigated.
With the synthesis of a half-loaded ICG dye, several new variations of the ICG
can be synthesized, each with unique properties depending on the substituents attached.
These half-loaded dye 36 were coupled to the mini carbon nanotubes to give 45. It is
hoped that a larger amount of the ICG could be brought to the hypoxic tumor at a time,
result in an increase in the observed fluorescence, and be retained in the tumor for an
extended period of time. As of the writing of this thesis, results for the biological testing
are pending.
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4. Future Work
With the synthesis of this half loaded ICG, many different derivatives can be
developed with various different properties. One such derivative would be to attach a
cytotoxic agent to one end of the dye, such as cisplatin (46) or carboplatin (47). Cisplatin
is a platinum based chemotherapy drug that works by binding to DNA, preferably
guanine, initiating cross-linking resulting in apoptosis. Carboplatin is a secondgeneration chemotherapy platinum agent with less side effects then cisplatin. It also
binds to DNA and results in apoptosis. Both compounds are currently being used to treat
various types of cancers, including ovarian, testicular, lung, and some pediatric tumors.39
By attaching a chemotherapeutic drug to the half-loaded dye (48), the conjugate
compound would be able to target the hypoxic tumor, exhibit fluorescence to image the
tumor, and kill the tumor all on one shot.

Figure 25: Cisplatin(46) and Carboplatin(47)
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Figure 26: Structure of Theoretical Half Loaded Dye with Carboplatin
Another compound that could be attached to the half loaded dye is biotin (49).
Biotin useful because it can be used as a label for protein detection and allows for easy
purification. This is due to its ability to strongly bind to the proteins avidin and
streptavidin.40 (Figure 28)
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Figure 27: Structure of Biotin
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Figure 28: Protein Structures for Avidin and Streptavidin41
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Adding a biotin unit to the half-loaded dye (49) would enable extraction and
isolation of any proteins associated with the hypoxic tumor that may be bound to the
nitroimidazole dye-conjugate. Once the hypoxic tumor has been excised from the mouse
and after treatment with the dye-conjugate, the cells can be passed through a column
containing beads of avidin. The biotinylated dye with the attached proteins should adhere
to the avidin beads, immobilizing the compounds, while everything else washes through
the column. If a protein is isolated, it may be possible to determine how the
nitroimidazole interacts with the hypoxic tumor, providing information that may allow
the synthesis of a more specific dye.

Figure 29 Structure of Theoretical Half-Loaded Dye Biotin Conjugate
A third use for the half loaded dye would be to quantify how much of the dye can
be attached to the carbon nanotubes. In order to do this, the amine would be attached to
the nanotube at multiple points, leaving only one nitrogen available for coupling with the
half-loaded dye. The amine would form a cage-like structure on the nanotube, with the
dye attached at a single point. (Figure 30) It is hoped that the nanotube could be
partially soluble so it could be analyzed by NMR. If the nanotubes still remain insoluble,
it is hoped that by attaching a spacer between the amine and the half loaded dye the
compound will become soluble enough to quantify the amount of dye attached to the
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nanotubes via NMR. Examples of suitable amine to try to attach to the nanotube to form
these amine cages are Tris[2-(methylamino)ethyl]amine (51), Bis(3-aminopropyl)amine
(52), and 1,2-Bis(3-aminopropylamino)ethane (53) .
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Figure 30: Example of Nanotube with Amine Cage Attached to Half-Loaded Dye

Figure 31: Suitable Amines to form Amine Cages on Nanotubes
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5. Experimental

General Information: All chemicals were purchased from Sigma Aldrich or Acros.
Unless indicated all chemicals and solvents were used as received. All glassware was
oven dried before use, unless water was used as a reagent. 1H and 13C NMR were
collected on Bruker Avance 300 (300.13 MHz 1H, 75.47 MHz 13C) or a Bruker DRX-400
(400.14 MHz 1H, 100.61 MHz 13C). Chemical shifts are given in ppm downfield from
TMS. All RAMAN spectra were collected on a Horiba Jovin Yovan T64000 Triple
Monochrometer Raman spectrometer, equipped with confocal microscope and lasersteering options, at a wavelength of 514 nm. All HRMS data was collected on a Qstar
Elite (AB Sciex) using DART-AccuTOF or ESI-AccuTOF methods.

2,3,3-Trimethyl-3H-indole-5-carboxylic acid (16):17

A 100 mL round-bottomed flask with a magnetic stirbar was charged with 4hydrazinobenzoic acid (4.50 g, 29.6 mmol), 3-methyl 2-butanone (4.60 mL, 42.9 mmol),
sodium acetate (4.86g, 59.2 mmol), and glacial acetic acid (55 mL). The mixture was
placed under nitrogen and stirred for 1 hour, then heated at reflux overnight. The mixture
was cooled to room temperature and the acetic acid was removed in vacuo. The resulting
solid was washed with 80 mL of 10% methanol in water. The resulting precipitate was
vacuum filtered off to yield a tan powder. (4.07 g, 20.0 mmol, 68%). Mp. Decompose,
205-208 °C. 1H NMR (CDCl3): δ 1.36 (s, 6H), 2.36 (s, 3H), 7.64 (d, J = 8.07 Hz, 1H),
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8.04 (d, J = 1.47 Hz, 1H), 8.14 (dd, J = 8.07 Hz, 1.71 Hz, 1H).

13

C NMR (CDCl3): δ

15.8, 23.1, 54.2, 119.9, 123.5, 126.9, 131.1, 145.9, 157.9, 171.4, 192.7.

5-Carboxy-1-(δ-sulfobutyl)-2,3,3-trimethyl-3H-indolium (17):17

A 100 mL round-bottomed flask with a magnetic stirbar was charged with indole acid
(16) (1.00 g, 4.92 mmol) 1,4 butanesultone (2.95 mL, 28.8 mmol), and 1,2
dichlorobenzene (20 mL). The mixture was heated at reflux under nitrogen overnight.
The mixture was cooled to room temperature, and then the precipitate was vacuum
filtered and washed with acetone to yield a pale red powder. (1.46 g, 4.31 mmol, 88%)
Mp. Decompose, 230-232 °C. 1H NMR (MeOD): δ 1.67 (s, 6H), 1.97 (m, 2H), 2.17 (m,
2H), 2.92 (t, J = 6.85 Hz, 2H), 4.61 (t, J = 7.82 Hz, 2H), 8.06 (d, J = 8.55 Hz, 1H), 8.32
(d, J = 8.55 Hz, 1H), 8.39 (s, 1H)

13

C NMR (MeOD): δ 22.6, 23.2, 27.3, 51.0, 56.2,

116.8, 125.6, 132.3, 133.7, 143.6, 145.6, 167.9, 201.1. (the single methyl group only is
visible in a 13C DEPT NMR (MeOD): δ 47.9)
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Bis-1-1′-(4-sulfobutyl)indoletricarbocyanine-5,5′-dicarboxylic acid sodium salt (9):17

A 100 mL round-bottomed flask with a magnetic stirbar was charged with the carboxylic
acid indolium salt (17) (1.02 g, 3.00 mmol) and N-[5-(Phenylamino)-2,4pentadienylidene]aniline monohydrochloride (0.344 g, 1.38 mmol). Then acetic
anhydride (15 mL) and glacial acetic acid (9 mL) was added to flask. The mixture was
stirred at room temperature as sodium acetate (0.40 g, 4.87 mmol) was added. The
system was refluxed under nitrogen for 45 minutes. The mixture was cooled to room
temperature, then poured into 150 mL of hot anhydrous ether. The solution was cooled at
5°C overnight, and then the precipitate was filtered off and washed with ether. The
collected solid was recrystallized in a 1:4 mixture of water and propanol. The resulting
crystals were filtered and dried for two days under vacuum to yield a green powder with a
metallic yellow tinge. (0.85 g, 1.11 mmol, 80%). Mp. Decompose, 249-251°C 1H NMR
(DMSO): δ 1.64 (s, 12H), 1.73 (bd s, 8H), 4.08 (bd s, 4H), 6.5 (d, J = 13.5 Hz, 2H), 6.63
(t, J = 12.0 Hz, 2H), 7.48 (d, J = 8.56 Hz, 2H), 7.94 (m, 5H), 8.06 (d, J = 1.46 Hz, 2H),
12.87 (bs, 2H).

13

C NMR (DMSO): δ 23.1, 26.7, 27.7, 44.4, 49.1, 51.3, 105.0, 111.5,

123.9, 126.7, 131.4, 167.6.
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5-Carboxylate-1-(δ-sulfobutyl)-2,3,3-trimethyl-3H-indolium (19):42

A 50 mL round-bottomed flask with a magnetic stirbar was charged with the carboxylic
acid indolium salt (17) (1.01 g, 2.97 mmol), and absolute methanol (15 mL). The
mixture was stirred at room temperature under nitrogen as oxalyl chloride (1.0 mL, 11.9
mmol) was added dropwise. Then the mixture was stirred for 24 hours. The mixture
was reduced in vacuo to give a red paste. The crude product was stirred in ether until it
became a suspension, about 24 hours. The solid was filtered and washed with ether to
yield a red powder. (1.02 g, 2.89 mmol, 97%). Mp. Decompose 159 °C. 1H NMR
(MeOD): δ 1.66 (s, 6H), 1.97 (bd s, 2H), 2.17 (bd s, 2H), 2.93 (bd s, 2H), 3.98 (s, 3H),
4.60 (bs, 2H), 8.06 (d, J = 7.34 Hz, 1H), 8.30 (d, J = 6.60 Hz, 1H), 8.39 (s, 1H).

13

C

NMR (MeOD): δ 22.6, 23.3, 27.3, 53.1, 56.3, 116.9, 125.5, 132.1, 133.0, 143.7, 145.8,
166.9, 201.3. HR-TOF MS: calculated for C17H24NO5S: m/z 354.1375. Found: m/z
354.1375.
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Bis-1-1′-(4-sulfobutyl)indoletricarbocyanine-5-carboxy-5′-carboxylate sodium salt
(18):17
O
HO
N

N
O

S
O

O

O
O
O S
O Na

O

A 100 mL round-bottomed flask with a magnetic stirbar was charged with the carboxylic
acid indolium salt (17) (0.50 g, 1.47 mmol) and N-[5-(Phenylamino)-2,4pentadienylidene]aniline monohydrochloride (0.37g, 1.49 mmol). Then acetic anhydride
(19 mL) and glacial acetic acid (12 mL) were added to flask. The mixture was stirred as
sodium acetate (0.48 g, 5.84 mmol) was added. The solution was heated at reflux under
nitrogen for 30 minutes. Next the methyl ester indolium salt (19) (0.54 g, 1.52 mmol)
was added to the flask, and the mixture continued to reflux for an additional 45 minutes.
The mixture was cooled to room temperature, then poured into 150 mL of hot anhydrous
ether. The solution was cooled at 5°C overnight, and then the precipitate was filtered and
washed with ether. The collected solid was recrystallized in a 1:4 mixture of water and
propanol. The crystals were filtered and dried for two days under vacuum to yield a blue
green powder. (0.96 g, 1.24 mmol, 83%) Mp. Decompose 238-239 °C. 1H NMR
(DMSO): δ 1.63 (s, 12H) 1.73 (bd s, 8H), 3.86 (s, 3H), 4.15 (d, J = 37.2 Hz, 4H), 6.48
(m, 4H), 7.47 (s, 1H), 7.52 (d, J = 9.05 Hz, 2H), 7.84 (m, 2H), 7.97 (d, J = 7.34 Hz, 2H),
8.08 (d, J = 7.34 Hz, 2H), 12.96 (bs, 1H)

13

C NMR (DMSO): δ 23.16, 26.8, 27.7, 41.8,

49.4, 51.4, 52.8, 123.8, 124.0, 125.6, 131.3, 142.0, 147.1, 166.6, 167.7. HR-TOF MS:
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Calculated for C38H46N2O10S2: m/z 755.2594. Found: m/z 755.2736 Calculated for
C38H45N2NaO10S2: m/z 777.2413. Found: m/z 777.2540.

Methyl 2-(4-nitro-1H-imidazol-1-yl)acetate (23a):17

A 50 mL round-bottomed flask with a magnetic stirbar was charged with 4nitroimidazole (1.00 g, 8.89 mmol), tetrabutylammonium iodide (0.075 g, 0.20 mmol),
potassium carbonate (1.80 g, 13.0 mmol), and freshly distilled acetonitrile (10 mL). The
mixture was stirred at room temperature under nitrogen for 30 minutes. Then methyl
bromoacetate (0.84 mL, 9.14 mmol) was added dropwise and system was heated at reflux
for an additional 40 minutes. The mixture was cooled to room temperature, and the
solids were filtered off, and washed with acetonitrile. The filtrate and washings was
removed in vacuo and the crude solid was recrystallized in ethyl acetate to yield a white
crystalline solid. (1.24 g, 6.70 mmol, 75%). Mp, 129-130 °C.
3.74 (s, 3H), 5.11 (s, 2H), 7.85. (s, 1H), 8.37 (s, 1H).

13

1

H NMR (DMSO): δ

C NMR (DMSO): δ 48.2, 52.5,

122.6, 138.3, 146.7, 168.0. HR-TOF MS: calculated for C6H8N3O4: m/z 186.0515.
Found: m/z 186.0532.
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Methyl 2-(2-nitro-1H-imidazol-1-yl)acetate (23b):17

A 50 mL round-bottomed flask with a magnetic stirbar was charged with 2nitroimidazole (0.093 g, 0.80 mmol) tetrabutylammonium iodide (0.013 g, 0.035 mmol),
potassium carbonate (0.174 g, 1.23 mmol), and freshly distilled acetonitrile (5 mL). The
mixture was stirred at room temperature under nitrogen for 30 minutes. Then methyl
bromoacetate (0.073 mL, 0.78 mmol) was added dropwise to the system. The solution
was heated under reflux for 40 minutes. The mixture was cooled, and the solids were
filtered off and washed with acetonitrile. The solvent was removed in vacuo, and the
resulting solid was placed under high vacuum to dry overnight. The crude solid was
recrystallized in ethyl acetate to yield an off-white crystalline solid. (0.06 g, 0.32 mmol,
40%) Mp, 95-96 °C. 1H NMR (CDCl3): δ 3.79 (s, 3H), 5.10 (s, 2H), 7.04 (s, 1H), 7.18
(s, 1H).

13

C NMR (CDCl3): δ 50.9, 53.4, 126.7, 128.7, 144.8, 166.7. HR-TOF MS:

calculated for C6H8N3O4: m/z 186.0515. Found: m/z 186.0529.
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N-(2-hydroxyethyl)-2-(4-nitro-1H-imidazol-1-yl)acetamide (24a):17

A 50 mL round-bottomed flask with a magnetic stirbar was charged with 4nitromethylester (23a) (0.65 g, 3.52 mmol), 6 mL of absolute methanol. Then
ethanolamine (0.90 mL, 14.9 mmol) was added dropwise, and the reaction was stirred
under nitrogen overnight at ambient temperature. The resulting solid was vacuum
filtered off, yielding a white solid. (0.61 g, 2.85 mmol, 81%) Mp. 136-137 °C. 1H NMR
(MeOD): δ 3.35 (t, J = 5.62 Hz, 2H), 3.63 (t, J = 5.38 Hz, 2H), 4.88 (s, 2H), 7.73 (s, 1H)
8.14 (s, 1H)

13

C NMR (MeOD): δ 43.1, 50.8, 61.2, 122.76, 139.2, 168.2. HR-TOF MS:

calculated for C7H11N4O4: m/z 215.0780. Found: m/z 215.0824.

N-(2-hydroxyethyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide (24b):17

A 50 mL round-bottomed flask with a magnetic stirbar was charged with 2nitromethylester (23b) (0.06 g, 0.33 mmol), 5 mL of absolute methanol. Ethanolamine
(0.08 mL, 1.32 mmol) was then added dropwise, and the reaction was stirred under
nitrogen overnight at ambient temperature. The methanol and excess ethanolamine were
removed in vacuo, yielding a yellow orange solid. (0.07 g, 0.33 mmol, 95%) Mp, 163.5-
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164.5 °C. 1H NMR (MeOD): δ 3.37 (t, J = 5.87 Hz, 2H), 3.62 (t, J = 5.62 Hz , 2H), 5.20
(s, 2H), 7.18 (s, 1H), 7.46 (s, 1H).

13

C NMR (MeOD): δ 43.2, 52.8, 61.4, 128.3, 129.3,

146.3, 168.3. HR-TOF MS: calculated for C7H11N4O4: m/z 215.0780. Found: m/z
215.0800.

2-(4-nitro-1H-imidazol-1-yl)acetic acid (27):42

A 50 mL round-bottomed flask with a magnetic stirbar was charged with 4nitroimidazole ester (23a) (1.00 g, 5.40 mmol), and 30 mL of water. The system was
heated under reflux for 24 hours. Then, the solution was cooled, and any remaining solid
was filtered off. The water was removed in vacuo, and solid was placed in drying pistol
with phosphorus pentoxide for 24 hours, to give a white solid (0.88 g, 5.14 mmol, 97%)
Mp, 151-152 °C. 1H NMR (DMSO): δ 4.98 (s, 2H), 7.83 (s, 1H), 8.37 (s, 1H).
NMR (MeOD): δ 53.3, 122.8, 139.2, 148.4, 170.0. HR-TOF MS: calculated for
C5H6N3O4: m/z 172.0358. Found: m/z 172.0369.
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13

C

2-(4-nitro-1H-imidazol-1-yl)acetyl chloride (28):43

A 50 mL round-bottomed flask with a magnetic stirbar was charged with dried 4nitroimidazole acid (27) (0.24 g, 1.37 mmol), freshly distilled tetrahydrofuran (10 mL),
and dried dimethylformamide (0.20 mL, 2.58 mmol). The system was placed under
nitrogen and cooled in ice bath. Then, oxalyl chloride (0.24 mL, 2.79 mmol) was added
dropwise to solution. The system was warmed to room temperature and stirred for 2
hours. The solution turned a bright yellow color when the reaction was complete. This
compound was used in situ. However no data could be collected on this product because
while attempting to isolate this product it hydrolyzed upon removal from the solution,
based on NMR and IR data.

Tert-butyl piperazine-1-carboxylate (25):

A 250 mL round bottom flask with a magnetic stirbar was charged with piperazine (3.42
g, 39.7 mmol), 47.5 mL of tert-butyl alochol, and 48.5 mL of distilled water. The flask
was placed in an ice bath, and 6.3 mL of 2.5 N NaOH was added dropwise, followed by
di-tert-butyl dicarbonate (3.48 g, 16.0 mmol). The contents of flask were stirred until
everything had dissolved, then it was removed from the ice bath and continued to stir at
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ambient temperature overnight. The mixture solvent was removed in vacuo, and the
resulting solid was taken up in water. The solution was extracted with three 35 mL
aliquots of DCM, then washed with three 25 mL aliquots of brine. The solution was
removed in vacuo to yield a white solid. (2.11 g, 11.3 mmol, 71%) Mp, 139-141 °C. 1H
NMR (CDCl3): δ 1.48 (s, 9H), 2.83 (t, J = 4.41 Hz, 4H) 3.41 (t, J = 5.37 Hz, 4H)

13

C

NMR (CDCl3): δ 28.7, 46.1, 79.8, 155.1.

Tert-butyl 4-(2-(4-nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (29):44

A solution of 4-nitroimidazole acid chloride (28) was prepared from 4-nitroimidazole
acid (27) (0.45 g, 2.64 mmol). The solution was cooled in an ice bath, and monosubstituted BOC-Piperazine (25) (2.93 g, 15.7 mmol) in 10 mL of dry THF was added via
canula. The mixture was stirred at room temperature for 1 hour, and then the solvents
were removed in vacuo. The solid was taken up in water, and the insoluble compounds
were filtered off. The remaining solid was then separated via column chromatography.
The solvent system for the column consisted of DCM and MeOH. The column began
with 100% DCM and in a gradient worked towards 5% MeOH in DCM, to give a fine
white powder. (0.21 g, 0.622 mmol, 23%) 1H NMR (CDCl3): δ 1.51 (s, 9H), 3.50 (bd s,
4H), 3.58 (bd s, 2H), 3.67 (bd s, 2H), 7.46 (s, 1H), 7.83 (s, 1H).
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13

C NMR (CDCl3): δ

28.2, 42.1, 44.6, 48.6, 80.6, 121.1, 137.1, 147.9, 154.2, 163.1, 180.8. HR-TOF MS:
calculated for C14H22N5O5: m/z 340.1621. Found: m/z 340.1607.

Tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (32):45

A 100 ml round bottom flask with a magnetic stirbar was charged with tert-butyl
piperazine-1-carboxylate (25) (0.78 g, 4.18 mmol) and dry dichloromethane (25 mL).
The flask was placed into an ice bath and triethylamine (0.63 mL, 4.55 mmol) was added,
then the mixture was stirred for 15 minutes. Next, α-bromoacetyl bromide (0.40 mL,
4.55 mmol) was added drop wise to the flask at 0°C and the mixture warmed to room
temperature and stirred overnight. The reaction progress was monitored by TLC. After
the reaction was complete, it was concentrated in vacuo and purified through column
chromatography, (15-20% petroleum ether in ethyl acetate) to yield a white solid (0.80 g,
2.60 mmol, 81%) was isolated. 1H NMR (CDCl3): δ 1.45 (s, 9H), 3.42 (t, J = 12 Hz, 2H),
3.48 (m, 4H), 3.58 (t, J = 8 Hz , 2H), 3.85 (s, 2H).

13

C NMR (CDCl3): δ 25.8¸ 28.6, 42.2,

46.8, 154.7, 165.7. HR-TOF MS: calculated for C11H19BrN2O3: m/z 307.0657. Found:
m/z 307.0652.
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Tert-butyl 4-(2-(2-nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (33):

A 50 ml round bottom flask with a magnetic stirbar was charged 2-nitroimidazole (0.10
g, 0.88 mmol) and dry DMF (1mL), and cooled to 0 °C. Then sodium hydride (0.025g,
0.11 mmol) was added and the mixture was stirred under nitrogen for 30 minutes. Next
tert-butyl 4-(2-bromoacetyl) piperazine-1-carboxylate (32) (0.30g, 0.98 mmol) was added
slowly and the reaction mixture was stirred at room temperature overnight. The DMF was
evaporated off and water (5 mL) was added to give white precipitate, which was filtered
and dried under vacuum, yielding a white powder (0.28 g, 0.825 mmol, 93%). Mp 150174°C.

1

H NMR (CDCl3): δ 1.46 (s, 9H), 3.46-3.45 (m, 2H), 3.50 (m, 2H), 3.60-3.57 (t,

J = 12Hz, 4H), 5.21 (s, 2H), 7.05 (s, 1H), 7.19-7.18 (d, J = 4Hz, 1H).

13

C NMR (CDCl3):

δ HR-TOF MS: calculated for C14H22N5O5: m/z 340.1621. Found: m/z 340.1608.

2-(4-nitro-1H-imidazol-1-yl)-1-(piperazin-1-yl)ethanone TFA salt (30):

A 50 mL round bottom flask was charged with a magnetic stirbar 4-nitroimidazole BOC
– Piperazine (29) (0.19 g, 0.551 mmol) and 13 mL of dry CHCl3 was added.
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Trifluoroacetic acid (1.0 mL, 13.0 mmol) was added dropwise, then the mixture stirred at
room temperature overnight under nitrogen. The chloroform was removed in vacuo, and
the crude solid was suspended in ethyl acetate. The solution was cooled in ice bath, the
flask was scratched and resulting solid was filtered, resulting in a white powder (0.123 g,
0.360 mmol, 94 %). Mp, 213-215 °C.

1

H NMR (D2O): δ 3.34 (t, 2H, J = 5.85 Hz) 3.42

(t, 2H, J = 4.10 Hz), 3.88 (t, 4H, J = 4.97 Hz), 5.30 (s, 2H), 7.71 (s, 1H), 8.13 (s, 1H).
13

C NMR (D2O): δ 39.3, 41.7, 42.9, 49.1, 123.1, 138.9, 146.7, 166.8. HR-TOF MS:

calculated for C10H14F3N5O5: m/z 240.1096. Found: m/z 240.1100.

2-(2-nitro-1H-imidazol-1-yl)-1-(piperazin-1-yl)ethanone TFA salt (31):

In 50 mL round bottom flask with a magnetic stirbar 2-nitroimidazole BOC – Piperazine
(33) (0.28 g, 0.83 mmol) and 10 mL of dry CHCl3 was added. Trifluoroacetic acid (1.0
mL, 23 mmol) was added dropwise, then the mixture was stirred at room temperature
overnight under nitrogen. The chloroform was removed in vacuo, and the crude solid
was suspended in ethyl acetate. The solution was cooled in an ice bath, and the flask was
scratched and resulting solid was vacuum filtered, resulting in a white powder (0.25 g,
0.732 mmol, 86%) Mp. 95-96 °C. 1H NMR (D2O): δ 3.49 (t, 2H) 3.59 (t, 2H), 4.01 (t,
2H), 4.08 (t, 2H), 5.68 (s, 2H), 7.40 (s, 1H), 7.58 (s, 1H).
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13

C NMR (D2O): δ 39.6, 42.2,

43.3, 51.3, 128.4, 129.2, 166.9. HR-TOF MS: calculated for C10H14F3N5O5: m/z
240.1096. Found: m/z 240.1149.

Sodium 4-(2-((1E,3E,5E,7Z)-7-(3,3-dimethyl-5-((2-(2-(4-nitro-1H-imidazol-1yl)acetamido)ethoxy)carbonyl)-1-(4-sulfonatobutyl)indolin-2-ylidene)hepta-1,3,5trienyl)-5-(methoxycarbonyl)-3,3-dimethyl-3H-indolium-1-yl)butane-1-sulfonate
(34a):46

A 25 mL round-bottomed flask with a magnetic stirbar was charged acid/ester dye (18)
(0.200 g, 0.257 mmol) and 2.5 mL of dry DMF, and placed under nitrogen. The flask
was cooled in an ice bath, then diisopropylethylamine (0.07 mL, 0.40 mmol) was added
dropwise, followed by an addition of benzotriazol-1-yl-oxytripyrrolidinophosphonium
hexafluorophosphate (PyBOP) (0.216 g, 0.415 mmol) and hydroxybenzotriazole (HOBt)
(0.053 g, 0.39 mmol). The contents were stirred at 0°C for 30 minutes, and then 4nitroethanolamine (24a) (0.055 g, 0.26 mmol) was added. The mixture was warmed to
room temperature, and continued to stir for 2 to 3 days. The DMF was slowly removed
by evaporation, induced by passing a stream of air over the liquid in the flask, and then
ethyl acetate was added to the resulting solid, and stirred for 20 minutes. The remaining
solid was filtered off, and then stirred in CHCl3 for 20 minutes. The solid was again
filtered, and then stirred in CH3CN for 20 minutes. The solid was filtered and then
adsorbed to reverse phase silica gel. The sample was then passed through a reverse phase
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automated column, using a gradient of 0% up to 40% methanol in water, resulting in dark
purple solid. (0.050 g, 0.051 mmol, 20%) Mp, Decompose > 200 °C. (Because this is
such a dark solid it was difficult to determine at what temperature it decomposed) 1H
NMR (DMSO): δ 1.67 (s, 12H), 1.75 (bd s, 8H), 3.52 (bd s, 2H), 3.87 (s, 3H), 4.12 (bd s,
4H), 4.31 (t, J = 5.38 Hz, 2H), 4.88 (s, 2H), 6.56 (d, J = 11.49 Hz, 2H), 6.67 (t, J = 11.25
Hz, 2H), 7.54 (t, J = 7.34 Hz, 2H), 7.80 (s, 1H), 7.92-8.00 (m, 6H), 8.11 (d, J = 5.62 Hz,
2H), 8.30 (s, 1H), 8.60 (t, J = 6.84 Hz, 1H)

13

C NMR: Sample has been submitted, but

unable to obtain a decent spectrum. HR-TOF MS: calculated for C45H55N6O13S2: m/z
951.3269. Found; m/z 951.3321. Calculated for C45H54N6NaO13S2: m/z 973.3088.
Found: m/z 973.3196.

Sodium 4-(2-((1E,3E,5E,7Z)-7-(3,3-dimethyl-5-((2-(2-(2-nitro-1H-imidazol-1yl)acetamido)ethoxy)carbonyl)-1-(4-sulfonatobutyl)indolin-2-ylidene)hepta-1,3,5trienyl)-5-(methoxycarbonyl)-3,3-dimethyl-3H-indolium-1-yl)butane-1-sulfonate
(34b):46

A 25 mL round-bottomed flask with magnetic stirbar was charged with the acid/ester dye
(18) (0.248 g, 0.319 mmol) and 2.5 mL of dry DMF, and placed under nitrogen. The
flask was cooled in an ice bath, then diisopropylethylamine (0.09 mL, 0.52 mmol) was
added dropwise, followed by an addition of benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (0.271 g, 0.520 mmol)
63

and hydroxybenzotriazole (HOBt) (0.072 g, 0.53 mmol). The contents were stirred at
0°C for 30 minutes, and then 2-nitroethanolamine (24b) (0.072 g, 0.33 mmol) was added.
The mixture was warmed to room temperature, and continued stirring for 2 to 3 days.
The DMF was slowly removed by evaporation, induced by passing a stream of air over
the liquid in the flask, and then ethyl acetate was added to the resulting solid, and stirred
for 20 minutes. The remaining solid was filtered off, and then stirred in CHCl3 for 20
minutes. The solid was again filtered, and then stirred in CH3CN for 20 minutes The
solid was filtered and then adsorbed to reverse phase silica gel. The sample was then
passed through a reverse phase automated column, using a gradient of 0% up to 40%
methanol in water, resulting in dark purple solid. (0.11 g, 0.11 mmol, 35%) Mp,
Decompose > 200 °C. (Because this is such a dark solid it was difficult to determine at
what temperature it decomposed) 1H NMR (DMSO): δ 1.67 (s, 12H), 1.74 (bd s, 8H),
3.53 (bd s, 2H), 3.71 (s, 3H), 4.11 (bd s, 4H), 4.29 (bd s, 2H), 5.14 (bd s, 2H), 6.54 (d, J =
13.21 Hz, 2H), 6.67 (t, J = 9.98 Hz, 3H), 7.53 (d, J = 8.31 Hz, 2H), 7.63 (s, 1H), 7.848.09 (m, 7H), 8.12 (s, 1H), 8.63 (t, J = 5.87 Hz 1H).

13

C NMR: Sample has been

submitted, but unable to obtain a decent spectrum.HR-TOF MS: calculated for
C45H55N6O13S2: m/z 951.3269. Found; m/z 951.3521. Calculated for
C45H54N6NaO13S2: m/z 973.3088. Found: m/z 973.3096.
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Sodium 4-(2-((1E,3E,5E,7Z)-7-(3,3-dimethyl-5-(4-(2-(4-nitro-1H-imidazol-1yl)acetyl)piperazine-1-carbonyl)-1-(4-sulfonatobutyl)indolin-2-ylidene)hepta-1,3,5trienyl)-5-(methoxycarbonyl)-3,3-dimethyl-3H-indolium-1-yl)butane-1-sulfonate
(35a):46

A 25 mL round-bottomed flask with a magnetic stirbar was charged with the acid/ester
dye (18) (0.199 g, 0.256 mmol) and 2.5 mL of dry DMF, and placed under nitrogen. The
flask was cooled in an ice bath, then diisopropylethylamine (0.07 mL, 0.401 mmol) was
added dropwise, followed by an addition of benzotriazol-1-yl
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (0.210 g, 0.403 mmol)
and hydroxybenzotriazole (HOBt) (0.054 g, 0.40 mmol). The contents were stirred at
0°C for 30 minutes, then 4-nitropiperazine (30) (0.065 g, 0.27 mmol) was added. The
mixture was warmed to room temperature, and continued stirring for 2 to 3 days. The
DMF was slowly removed by evaporation, induced by passing a stream of air over the
liquid in the flask, and then ethyl acetate was added to the resulting solid, and stirred for
20 minutes. The remaining solid was filtered off, and then stirred in CHCl3 for 20
minutes. The solid was again filtered, and then stirred in CH3CN for 20 minutes. The
solid was filtered and then adsorbed to reverse phase silica gel. The sample was then
passed through a reverse phase automated column, using a gradient of 0% up to 70%
methanol in water, resulting in dark purple solid. No data was gathered on this
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compound, because compound had decomposed due to excessive heating while trying to
isolate. Believed to initially have compound based on TLC analysis, but was not
repeated because methyl ester could not be removed.

Sodium 4-(5-carboxy-2-((1E,3E,5E,7Z)-7-(3,3-dimethyl-5-((2-(2-(4-nitro-1Himidazol-1-yl)acetamido)ethoxy)carbonyl)-1-(4-sulfonatobutyl)indolin-2ylidene)hepta-1,3,5-trienyl)-3,3-dimethyl-3H-indolium-1-yl)butane-1-sulfonate
(36a):46

A 25 mL round-bottomed flask with a magnetic stirbar was charged with the biscarboxylic acid ICG dye (9) (0.160g, 0.210 mmol) and 2.5 mL of dry DMF, and placed
under nitrogen. The flask was cooled in an ice bath, then diisopropylethylamine (0.050
mL, 0.35 mmol) was added dropwise, followed by an addition of benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (0.177 g, 0.340 mmol)
and hydroxybenzotriazole (HOBt) (0.046 g, 0.34 mmol). The contents were stirred at
0°C for 30 minutes, then 1 equivalent of 4-nitroethanolamine (24a) (0.047 g, 0.22 mmol)
was added. The mixture was warmed to room temperature, and continued stirring for 2
to 3 days. The DMF was slowly removed by evaporation, induced by passing a stream of
air over the liquid in the flask, and then ethyl acetate was added to the resulting solid, and
stirred for 20 minutes. The remaining solid was filtered off, and then stirred in CHCl3 for
20 minutes. The solid was again filtered, and then stirred in CH3CN for 20 minutes. The
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solid was filtered and then adsorbed to reverse phase silica gel. The sample was then
passed through a reverse phase automated column, using a gradient of 0% up to 70%
methanol in water, resulting in dark purple solid. (0.067 g, 0.070 mmol, 33%) Mp,
Decompose > 200 °C. (Because this is such a dark solid it was difficult to determine at
what temperature it decomposed) 1H NMR (DMSO): δ 1.67 (s, 12H), 1.75 (bd s, 8H),
3.52 (bd s, 2H), 3.87 (s, 3H), 4.12 (bd s, 4H), 4.31 (t, J = 5.38 Hz, 2H), 4.88 (s, 2H), 6.56
(d, J = 11.49 Hz, 2H), 6.67 (t, J = 11.25 Hz, 2H), 7.54 (t, J = 7.34 Hz, 2H), 7.80 (s, 1H),
7.92-8.00 (m, 6H), 8.11 (d, J = 5.62 Hz, 2H), 8.30 (s, 1H), 8.60 (t, J = 6.84 Hz, 1H),
12.93 (bd s, 1H).

13

C NMR: Sample has been submitted, but unable to obtain a decent

spectrum. HR-TOF MS: calculated for C44H51N6O13S2: m/z 937.3112. Found; m/z
937.3123. Calculated for C44H51N6NaO13S2: m/z 959.2931. Found: m/z 959.2970.

Sodium 4-(5-carboxy-2-((1E,3E,5E,7Z)-7-(3,3-dimethyl-5-((2-(2-(2-nitro-1Himidazol-1-yl)acetamido)ethoxy)carbonyl)-1-(4-sulfonatobutyl)indolin-2ylidene)hepta-1,3,5-trienyl)-3,3-dimethyl-3H-indolium-1-yl)butane-1-sulfonate
(36b):46

O

O
N

N

HO

O
NH
O

O

S
O

O

O

S
O

O Na

N

NO2
N

A 25 mL round-bottomed flask with a magnetic stirbar was charged with the biscarboxylic acid ICG dye (9) (0.192 g, 0.252 mmol) and 2.5 mL of dry DMF, and placed
under nitrogen. The flask was cooled in an ice bath, then diisopropylethylamine (0.05
mL, 0.35 mmol) was added dropwise, followed by an addition of benzotriazol-1-yl67

oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (0.176 g, 0.338 mmol)
and hydroxybenzotriazole (HOBt) (0.046 g, 0.34 mmol). The contents were stirred at
0°C for 30 minutes, then 1 equivalent of 2-nitroethanolamine (24b) (0.060 g, 0.27 mmol)
was added. The mixture was warmed to room temperature, and continued stirring for 2
to 3 days. The DMF was slowly removed by evaporation, induced by passing a stream of
air over the liquid in the flask, and then ethyl acetate was added to the resulting solid, and
stirred for 20 minutes. The remaining solid was filtered off, and then stirred in CHCl3 for
20 minutes. The solid was again filtered, and then stirred in CH3CN for 20 minutes.
Then placed under a high vacuum to dry, resulting in a dark blue green solid, however
this is a mixture of starting material and product. If ran on the Combi Flash there would
not be enough material for the next step. (0.172 g, 0.179 mmol, 72%) Mp, Decompose >
200 °C. (Because this is such a dark solid it was difficult to determine at what
temperature it decomposed) 1H NMR (DMSO): δ 1.65 (s, 12H), 1.73 (bd s, 8H), 3.53 (bd
s, 2H), 4.09 (bd s, 4H), 4.29 (bd s, 2H), 5.08 (bd s, 2H), 6.46 (d, J = 12.21 Hz, 2H), 6.62
(t, J = 15.23 Hz, 3H), 7.46 (t, J = 4.64 Hz, 2H), 7.75 (d, J = 8.32 Hz, 2H), 7.84 (s, 1H),
7.91-8.05 (m, 7H), 8.14 (s, 1H), 8.47 (t, J = 5.87 Hz 1H), 12.92 (bd s, 1H).

13

C NMR:

Sample has been submitted, but unable to obtain a decent spectrum. HR-TOF MS:
calculated for C44H51N6O13S2: m/z 937.3112. Found; m/z 937.3244. Calculated for
C44H51N6NaO13S2: m/z 959.2931. Found: m/z 959.2865.
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Sodium 4-(5-carboxy-2-((1E,3E,5E,7Z)-7-(3,3-dimethyl-5-(4-(2-(4-nitro-1Himidazol-1-yl)acetyl)piperazine-1-carbonyl)-1-(4-sulfonatobutyl)indolin-2ylidene)hepta-1,3,5-trienyl)-3,3-dimethyl-3H-indolium-1-yl)butane-1-sulfonate
(37a):46

A 25 mL round-bottomed flask with a magnetic stirbar was charged with the biscarboxylic acid ICG dye (9) (0.151 g, 0.202 mmol) and 2.5 mL of dry DMF, and placed
under nitrogen. The flask was cooled in an ice bath, then diisopropylethylamine (0.056
mL, 0.32 mmol) was added dropwise, followed by an addition of benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (0.166 g, 0.323 mmol)
and hydroxybenzotriazole (HOBt) (0.0434 g, 0.32 mmol). The contents were stirred at
0°C for 30 minutes, then 1 equivalent of 4-nitropiperazine (30) (0.065 g, 0.20 mmol) was
added. The mixture was warmed to room temperature, and continued stirring for 2 to 3
days. The DMF was slowly removed by evaporation, induced by passing a stream of air
over the liquid in the flask, and then ethyl acetate was added to the resulting solid, and
stirred for 20 minutes. The remaining solid was filtered off, and then stirred in CHCl3 for
20 minutes. The solid was again filtered, and then stirred in CH3CN for 20 minutes. The
solid was filtered and then adsorbed to reverse phase silica gel. The sample was then
passed through a reverse phase automated column, using a gradient of 0% up to 70%
methanol in water, resulting in dark purple solid. (0.030 g, 0.030 mmol, 16 %) Mp,
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Decompose > 200 °C. (Because this is such a dark solid it was difficult to determine at
what temperature it decomposed) 1H NMR (DMSO): δ 1.67 (s, 12H), 1.74 (bd s, 8H),
3.13 (bd s, 4H), 3.59 (bd s, 4H), 4.11 (bd s, 4H), 4.60 (s, 2H), 5.20 (bd s, 2H), 6.49 (d, J =
14.18 Hz, 2H), 6.65 (t, J = 11.01 Hz, 3H), 7.52 (m, 2H), 7.74 (s, 1H), 7.56-8.15 (m, 7H),
8.26 (s, 1H), 12.90 (bd s, 1H)

13

C NMR: Sample has been submitted, but unable to

obtain a decent spectrum. HR-TOF MS: calculated for C46H54N7O12S2: m/z 962.3428.
Found; m/z 962.3513. Calculated for C46H54N7NaO12S2: m/z 984.3248. Found: m/z
984.3255.

Amine Functionalized Single Walled Carbon Nanotubes (41):36

Prepared by Mr. Saied Zanganeh from the University of Connecticut Department of
Electrical and Computer Engineering. The SWCNTs were immersed in a mixture of
H2SO4 and HNO3 (3:1) at room temperature. Then treated in an ultrasound bath for 2
hours and suspended for 15 hours. Next hydrochloric acid was added to the solution.
The solution was neutralized with ammonium hydroxide and filtered through a 0.22 mm
cellulose acetate membrane. The SWCNTs were washed several times with deionized
water until pH 5.5 was reached. The residue was dried in an 80°C vacuum oven for 12
hours to obtain carboxylated carbon nanotubes SWCNT-COOH. These were then
reacted with thionyl chloride, resulting in SWCNT functionalized with acid chlorides
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moieties, SWCNT-COCl. Next, the acid chloride SWCNT was reacted with
triethylenetetramine generating SWCNT-NH2. Addition of the functional groups is
confirmed via dispersion in aqueous solutions. Non-fuctionalized SWCNTs do not
disperse, functionalized SWCNTs do because the presence of same-sized charged
particles on the surface of SWCNTs enables the SWCNTs to repel from each other,
keeping them dispersed in solution.

Bis-Carboxylic Acid ICG Coupled to Amine Functionalized Single Walled Carbon
Nanotubes (43):36
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Bis-carboxylic acid ICG (9) (0.192 g, 0.25 mmol) was dissolved in oxalyl chloride (1
mL, 11.7 mmol) and stirred at room temperature under nitrogen until the formation of
bubbles stopped. The an additional amount of oxalyl chloride (1 mL, 22.7 mmol) was
added and the solution was refluxed for 1 hour. The solution was cooled, the solvents
were removed, and the resulting solid placed under high vacuum overnight. To this solid,
3 mL of dry toluene was added followed by amine functionalized SWNTs (0.064 g). The
mixture was stirred at room temperature for 1 hour and then heated at reflux overnight.
The mixture was cooled, and then the solid was filtered off. The solid was taken up with
water and filtered. This was repeated until the filtrate is no longer colored green to give a
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black and green solid (0.07g). It is unknown exactly where and how many ICG dye were
bound to the SWNT. Raman Analysis: 1140.39, 1373.43, 1594.43 cm-1.

Half Loaded 2-Nitroimidazole Ethanolamine ICG Coupled to Amine Functionalized
Single Walled Carbon Nanotubes (45):36

A round bottom flask with a magnetic stirbar was charged with half loaded 2nitroethanolamine ICG (36b) (0.172 g, 0.179 mmol) was dissolved in oxalyl chloride (1
mL, 11.7 mmol) and stirred at room temperature under nitrogen until the formation of
bubbles stopped. The an additional amount of oxalyl chloride (1 mL, 22.7 mmol) was
added and the solution was refluxed for 1 hour. The solution was cooled, the solvents
were removed, and the resulting solid placed under high vacuum overnight. To this solid,
3 mL of dry toluene was added followed by amine functionalized SWNTs (0.054 g). The
mixture was stirred at room temperature for 1 hour and then heated at reflux overnight.
The mixture was cooled, and then the solid was filtered off. The solid was taken up with
water and filtered. This was repeated until the filtrate is no longer colored green to give a
black and green solid (0.099 g). It is unknown exactly where and how many half loaded
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2-nitroethanolamine ICG (36b) were bound to the SWNT. Raman Analysis: 1140.52,
1373.64, 1599.50, 2693.26 cm-1.
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